Company set to introduce psychedelic product catalogue showcasing in-house EU-GMP manufacturing expertise VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances…

Source

Previous articleFILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN HEALTH CANADA-APPROVED PSILOCYBIN CLINICAL TRIAL
Next articleCOMPASS Pathways to participate in three upcoming investor events